{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T01:17:28Z","timestamp":1773278248447,"version":"3.50.1"},"reference-count":104,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T00:00:00Z","timestamp":1672790400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>Background: Follitropin delta is the third recombinant human follicle-stimulating hormone (r-hFSH) expressed in a host cell line of human fetal retinal origin that currently emphasizes that the actual tendency of administration is a personalized dosing algorithm based on the anti-M\u00fcllerian hormone (AMH) and body mass index (BMI) for ovarian stimulation. Methods: In this context, we aimed, in the present manuscript, to gather all available data published between 2018\u20132022 regarding the co-administration and administration of follitropin delta and the clinical outcomes reported following an in vitro fertilization (IVF). Results: Follitropin delta is non-inferior in contrast to its previously launched agents for ovarian stimulation, enhancing a similar-to-superior response reflected by both the reproductive and pregnancy outcomes in parallel with a low risk of ovarian hyperstimulation syndrome (OHSS), being well tolerated. The body weight and AMH level are factors that may influence the outcome in a patient. Despite controversy and results that refute these arguments on several occasions, follitropin delta exceeds the benefits of conventional dosing with either follitropin alfa or follitropin beta. Thus, all post hoc, derived analyses and subsets of patients that participated in subsequent studies support this statement. Conclusions: Despite the relatively limited spectrum of data in the current literature, most authors brought potent proof, supporting the subsequent use of this drug depending on the patient\u2019s profile and overcoming ethnic-related limitations. Although others contradict these observations, this topic and drug possess substantial potential, which is why additional studies are mandatory to fill the existing gaps in our knowledge and expand these experiences at a larger scale supported by the obtained reproductive and clinical outcomes that clearly indicate an overcoming of all limitations.<\/jats:p>","DOI":"10.3390\/diagnostics13020177","type":"journal-article","created":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T05:02:30Z","timestamp":1672808550000},"page":"177","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["A Narrative Review Discussing the Efficiency of Personalized Dosing Algorithm of Follitropin Delta for Ovarian Stimulation and the Reproductive and Clinical Outcomes"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6618-141X","authenticated-orcid":false,"given":"Bogdan","family":"Doroftei","sequence":"first","affiliation":[{"name":"Faculty of Medicine, University of Medicine and Pharmacy \u201cGrigore T. Popa\u201d, University Street, no 16, 700115 Iasi, Romania"},{"name":"Clinical Hospital of Obstetrics and Gynecology \u201cCuza Voda\u201d, Cuza Voda Street, no 34, 700038 Iasi, Romania"},{"name":"Origyn Fertility Center, Palace Street, no 3C, 700032 Iasi, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4023-1765","authenticated-orcid":false,"given":"Ovidiu-Dumitru","family":"Ilie","sequence":"additional","affiliation":[{"name":"Department of Biology, Faculty of Biology, \u201cAlexandru Ioan Cuza\u201d University, Carol I Avenue, no 20A, 700505 Iasi, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4987-5049","authenticated-orcid":false,"given":"Nicoleta","family":"Anton","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Medicine and Pharmacy \u201cGrigore T. Popa\u201d, University Street, no 16, 700115 Iasi, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6530-5700","authenticated-orcid":false,"given":"Olivia-Andreea","family":"Marcu","sequence":"additional","affiliation":[{"name":"Department of Preclinics, Faculty of Medicine and Pharmacy, University of Oradea, December 1 Market Street, no 10, 410068 Oradea, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioana-Sadyie","family":"Scripcariu","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Medicine and Pharmacy \u201cGrigore T. Popa\u201d, University Street, no 16, 700115 Iasi, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ciprian","family":"Ilea","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Medicine and Pharmacy \u201cGrigore T. Popa\u201d, University Street, no 16, 700115 Iasi, Romania"},{"name":"Clinical Hospital of Obstetrics and Gynecology \u201cCuza Voda\u201d, Cuza Voda Street, no 34, 700038 Iasi, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,1,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1007\/BF01728562","article-title":"Hypophysenvorderlappenhormon und Ovarialhormon im Harn von Schwangeren","volume":"6","author":"Aschheim","year":"1927","journal-title":"Klin. Wochenschr."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.fertnstert.2018.06.005","article-title":"Forty years of IVF","volume":"110","author":"Niederberger","year":"2018","journal-title":"Fertil. Steril."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.shpsc.2013.12.002","article-title":"The demand for pregnancy testing: The Aschheim-Zondek reaction, diagnostic versatility, and laboratory services in 1930s Britain","volume":"47","year":"2014","journal-title":"Stud. Hist. Philos. Biol. Biomed. Sci."},{"key":"ref_4","first-page":"26","article-title":"Hormone production by placental cells maintained in continuous culture","volume":"72","year":"1943","journal-title":"Bull Johns Hopkins Hosp."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s12522-011-0097-2","article-title":"Gonadotropin stimulation: Past, present and future","volume":"11","author":"Lunenfeld","year":"2012","journal-title":"Reprod. Med. Biol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/aja.1000400202","article-title":"Experimental evidence regarding the r\u00f4le of the anterior pituitary in the development and regulation of the genital system","volume":"40","author":"Smith","year":"1927","journal-title":"Am. J. Anat."},{"key":"ref_7","first-page":"834","article-title":"Weitere untersuchungen zur darstellung, biologie und klinik des hypophysenvorderlappenhormones (Prolan)","volume":"14","author":"Zondek","year":"1929","journal-title":"Zentralbl. Gynakol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"429","DOI":"10.3389\/fendo.2019.00429","article-title":"The Development of Gonadotropins for Clinical Use in the Treatment of Infertility","volume":"10","author":"Lunenfeld","year":"2019","journal-title":"Front. Endocrinol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"379","DOI":"10.2174\/138920112799361918","article-title":"Present and Future of Recombinant Gonadotropins in Reproductive Medicine","volume":"13","author":"Tosti","year":"2012","journal-title":"Curr. Pharm. Biotechnol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1093\/humupd\/2.2.172","article-title":"Genetic engineering of human FSH (Gonal-F\u00ae)","volume":"2","author":"Howles","year":"1996","journal-title":"Hum. Reprod. Update"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1093\/molehr\/2.5.371","article-title":"Recombinat hormones: Molecular biology and biochemistry of human recombinant follicle stimulating hormone (Puregon\u00ae)","volume":"2","author":"Olijve","year":"1996","journal-title":"Mol. Hum. Reprod."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"279","DOI":"10.6061\/clinics\/2014(04)10","article-title":"Gonadotropin therapy in assisted reproduction: An evolutionary perspective from biologics to biotech","volume":"69","author":"Esteves","year":"2014","journal-title":"Clinics"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2165\/00063030-199809030-00006","article-title":"Follitropin Alpha in Infertility","volume":"9","author":"Goa","year":"1998","journal-title":"BioDrugs"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1093\/molehr\/2.5.361","article-title":"Recombinat hormones: Structure-function relationship of recombinant follicle stimulating hormone (Puregon\u00ae)","volume":"2","author":"Mulders","year":"1996","journal-title":"Mol. Hum. Reprod."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.rbmo.2017.03.020","article-title":"Biosimilars to recombinant human FSH medicines: Comparable efficacy and safety to the original biologic","volume":"35","author":"Fauser","year":"2017","journal-title":"Reprod. Biomed. Online"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"636038","DOI":"10.3389\/fendo.2021.636038","article-title":"New Human Follitropin Preparations: How Glycan Structural Differences May Affect Biochemical and Biological Function and Clinical Effect","volume":"12","author":"Dias","year":"2021","journal-title":"Front. Endocrinol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1002\/jcph.328","article-title":"Different pharmacokinetic and pharmacodynamic properties of recombinant follicle-stimulating hormone (rFSH) derived from a human cell line compared with rFSH from a non-human cell line","volume":"54","author":"Olsson","year":"2014","journal-title":"J. Clin. Pharmacol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1530\/EC-17-0067","article-title":"Comparative pharmacology of a new recombinant FSH expressed by a human cell line","volume":"6","author":"Koechling","year":"2017","journal-title":"Endocr. Connect."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.rbmo.2018.10.012","article-title":"Follitropin delta in repeated ovarian stimulation for IVF: A controlled, assessor-blind Phase 3 safety trial","volume":"38","author":"Bosch","year":"2019","journal-title":"Reprod. Biomed. Online"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1016\/j.fertnstert.2020.10.059","article-title":"Randomized, assessor-blind, antim\u00fcllerian hormone-stratified, dose-response trial in Japanese in vitro fertilization\/intracytoplasmic sperm injection patients undergoing controlled ovarian stimulation with follitropin delta","volume":"115","author":"Ishihara","year":"2021","journal-title":"Fertil. Steril."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.xfre.2020.12.002","article-title":"In vitro fertilization cycles stimulated with follitropin delta result in similar embryo development and quality when compared with cycles stimulated with follitropin alfa or follitropin beta","volume":"2","author":"Haakman","year":"2021","journal-title":"F&S Rep."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.rbmo.2021.08.024","article-title":"Clinical outcomes of potential high responders after individualized FSH dosing based on anti-M\u00fcllerian hormone and body weight","volume":"43","author":"Papaleo","year":"2021","journal-title":"Reprod. Biomed. Online"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.rbmo.2021.01.023","article-title":"Individualized follitropin delta dosing reduces OHSS risk in Japanese IVF\/ICSI patients: A randomized controlled trial","volume":"42","author":"Ishihara","year":"2021","journal-title":"Reprod. Biomed. Online"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1093\/humrep\/deab155","article-title":"A randomised controlled trial to clinically validate follitropin delta in its individualised dosing regimen for ovarian stimulation in Asian IVF\/ICSI patients","volume":"36","author":"Qiao","year":"2021","journal-title":"Hum. Reprod."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.rbmo.2021.12.013","article-title":"An eight centre, retrospective, clinical practice data analysis of algorithm-based treatment with follitropin delta","volume":"44","author":"Bachmann","year":"2022","journal-title":"Reprod. Biomed. Online"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1093\/humrep\/deac061","article-title":"A randomized, controlled, first-in-patient trial of choriogonadotropin beta added to follitropin delta in women undergoing ovarian stimulation in a long GnRH agonist protocol","volume":"37","author":"Larsson","year":"2022","journal-title":"Hum. Reprod."},{"key":"ref_27","unstructured":"(2022, December 12). A Trial to Compare the Ovarian Response of REKOVELLE and GONAL-F in Conventional Dosing in Women Undergoing Controlled Ovarian Stimulation (ADAPT-1), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05263388."},{"key":"ref_28","unstructured":"(2022, December 12). Real-World Evidence on Follitropin Delta Individual Dosing, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05173597?cond=NCT05173597&draw=2&rank=1."},{"key":"ref_29","unstructured":"(2022, December 12). Trial to Assess the Pattern of Use of REKOVELLE\u00ae in Women Undergoing In Vitro Fertilisation (IVF) or Intracytoplasmic Sperm Injection (ICSI) Procedures in Routine Clinical Practice (NORSOS), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05499052?cond=NCT05499052&draw=2&rank=1."},{"key":"ref_30","unstructured":"(2022, December 12). Efficacy and Safety of FE 999049 in Controlled Ovarian Stimulation in India Women (IRIS), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04773353?cond=NCT04773353&draw=2&rank=1."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.rbmo.2020.07.006","article-title":"Establishing the follitropin delta dose that provides a comparable ovarian response to 150 IU\/day follitropin alfa","volume":"41","author":"Arce","year":"2020","journal-title":"Reprod. Biomed. Online"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1007\/s10815-021-02271-5","article-title":"Pregnancy and neonatal outcomes in fresh and frozen cycles using blastocysts derived from ovarian stimulation with follitropin delta","volume":"38","author":"Havelock","year":"2021","journal-title":"J. Assist. Reprod. Genet."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1111\/cen.13956","article-title":"Anti-M\u00fcllerian hormone variability and its implications for the number of oocytes retrieved following individualized dosing with follitropin delta","volume":"90","author":"Nelson","year":"2019","journal-title":"Clin. Endocrinol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.fertnstert.2016.10.033","article-title":"Individualized versus conventional ovarian stimulation for in vitro fertilization: A multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial","volume":"107","author":"Nelson","year":"2017","journal-title":"Fertil. Steril."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.rbmo.2021.09.014","article-title":"Comparison of ovarian response to follitropin delta in Japanese and White IVF\/ICSI patients","volume":"44","author":"Ishihara","year":"2022","journal-title":"Reprod. Biomed. Online"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.fertnstert.2020.09.158","article-title":"Individualized ovarian stimulation for in vitro fertilization: A multicenter, open label, exploratory study with a mixed protocol of follitropin delta and highly purified human menopausal gonadotropin","volume":"115","author":"Bissonnette","year":"2021","journal-title":"Fertil. Steril."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.rbmo.2018.12.032","article-title":"Individualization of the starting dose of follitropin delta reduces the overall OHSS risk and\/or the need for additional preventive interventions: Cumulative data over three stimulation cycles","volume":"38","author":"Visnova","year":"2019","journal-title":"Reprod. Biomed. Online"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.rbmo.2015.05.015","article-title":"Investigating the effect of ethnicity on IVF outcome","volume":"31","author":"Dhillon","year":"2015","journal-title":"Reprod. Biomed. Online"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1111\/1471-0528.14241","article-title":"Effect of ethnicity on live birth rates after in vitro fertilisation\/intracytoplasmic sperm injection treatment: Analysis of UK national database","volume":"124","author":"Maalouf","year":"2017","journal-title":"BJOG An Int. J. Obstet. Gynaecol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.fertnstert.2016.03.007","article-title":"Racial and ethnic disparities in assisted reproductive technology access and outcomes","volume":"105","author":"Quinn","year":"2016","journal-title":"Fertil. Steril."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"603","DOI":"10.3389\/fendo.2018.00603","article-title":"The Impact of the Biological Variability or Assay Performance on AMH Measurements: A Prospective Cohort Study with AMH Tested on Three Analytical Assay-Platforms","volume":"9","author":"Bungum","year":"2018","journal-title":"Front. Endocrinol."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Doroftei, B., Ilie, O.-D., Dabuleanu, A.-M., Diaconu, R., Maftei, R., Simionescu, G., and Ilea, C. (2021). Follitropin Delta as a State-of-the-Art Incorporated Companion for Assisted Reproductive Procedures: A Two Year Observational Study. Medicina, 57.","DOI":"10.3390\/medicina57040379"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1080\/17425247.2019.1651290","article-title":"An evaluation of the use and handling errors of currently available recombinant human follicle-stimulating hormone pen injectors by women with infertility and fertility nurses","volume":"16","author":"Longobardi","year":"2019","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1093\/oxfordjournals.humrep.a135740","article-title":"A prospective, randomized, assessor-blind, multicentre study comparing recombinant and urinary follicle stimulating hormone (Puregon versus Metrodin) in in-vitro fertilization","volume":"10","author":"Out","year":"1995","journal-title":"Hum. Reprod."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Recombinant Human FSH Study Group (1995). Clinical assessment of recombinant human follicle-stimulating hormone in stimulating ovarian follicular development before in vitro fertilization. Fertil. Steril., 63, 77\u201386.","DOI":"10.1016\/S0015-0282(16)57300-2"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1093\/humrep\/der163","article-title":"Repeated ovarian stimulation with corifollitropin alfa in patients in a GnRH antagonist protocol: No concern for immunogenicity","volume":"26","author":"Norman","year":"2011","journal-title":"Hum. Reprod."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.rbmo.2015.01.005","article-title":"A multi-centre phase 3 study comparing efficacy and safety of Bemfola(\u00ae) versus Gonal-f(\u00ae) in women undergoing ovarian stimulation for IVF","volume":"30","author":"Rettenbacher","year":"2015","journal-title":"Reprod. Biomed. Online"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12958-016-0164-y","article-title":"Safety and efficacy of Ovaleap\u00ae (recombinant human follicle-stimulating hormone) for up to 3 cycles in infertile women using assisted reproductive technology: A phase 3 open-label follow-up to Main Study","volume":"14","author":"Strowitzki","year":"2016","journal-title":"Reprod. Biol. Endocrinol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1006\/bbrc.2001.6059","article-title":"An Immunoreactive Peptide of the FSH Involved in Autoimmune Infertility","volume":"289","author":"Gobert","year":"2001","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_50","first-page":"762541","article-title":"Review on Autoimmune Reactions in Female Infertility: Antibodies to Follicle Stimulating Hormone","volume":"2012","author":"Salumets","year":"2012","journal-title":"Clin. Dev. Immunol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/j.1600-0897.2006.00428.x","article-title":"Association of Unexplained Infertility with Gonadotropin and Ovarian Antibodies","volume":"56","author":"Shatavi","year":"2006","journal-title":"Am. J. Reprod. Immunol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/j.fertnstert.2008.07.1725","article-title":"Repeated in vitro fertilization cycle attempts in patients undergoing controlled ovarian hyperstimulation with use of gonadotropin-releasing hormone antagonists","volume":"91","author":"Rabinson","year":"2009","journal-title":"Fertil. Steril."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/S0301-2115(02)00036-2","article-title":"Increasing the gonadotrophin dose in the course of an in vitro fertilization cycle does not rectify an initial poor response","volume":"103","author":"Khalaf","year":"2002","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1093\/oxfordjournals.humrep.a138053","article-title":"Doubling the human menopausal gonadotrophin dose in the course of an in-vitro fertilization treatment cycle in low responders: A randomized study","volume":"8","author":"Alberda","year":"1993","journal-title":"Hum. Reprod."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1016\/j.fertnstert.2014.08.013","article-title":"Ovarian response to recombinant human follicle-stimulating hormone: A randomized, antim\u00fcllerian hormone-stratified, dose-response trial in women undergoing in vitro fertilization\/intracytoplasmic sperm injection","volume":"102","author":"Arce","year":"2014","journal-title":"Fertil. Steril."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1111\/cen.12864","article-title":"Follicular and endocrine dose responses according to anti-M\u00fcllerian hormone levels in IVF patients treated with a novel human recombinant FSH (FE 999049)","volume":"83","author":"Bosch","year":"2015","journal-title":"Clin. Endocrinol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/rmb2.12358","article-title":"Assisted reproductive technology in Japan: A summary report for 2018 by the Ethics Committee of the Japan Society of Obstetrics and Gynecology","volume":"20","author":"Ishihara","year":"2021","journal-title":"Reprod. Med. Biol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.fertnstert.2005.07.1292","article-title":"Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles","volume":"85","author":"Papanikolaou","year":"2006","journal-title":"Fertil. Steril."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.fertnstert.2013.12.026","article-title":"Oocyte number as a predictor for ovarian hyperstimulation syndrome and live birth: An analysis of 256,381 in vitro fertilization cycles","volume":"101","author":"Steward","year":"2014","journal-title":"Fertil. Steril."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s12522-015-0211-y","article-title":"A multi-center, randomized, open-label, parallel group study of a natural micronized progesterone vaginal tablet as a luteal support agent in Japanese women undergoing assisted reproductive technology","volume":"14","author":"Fujiwara","year":"2015","journal-title":"Reprod. Med. Biol."},{"key":"ref_61","first-page":"3","article-title":"Ovarian hyperstimulation syndrome: Current views on pathophysiology, risk factors, prevention, and management","volume":"6","author":"Alper","year":"2009","journal-title":"J. Exp. Clin. Assist. Reprod."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s40261-015-0276-8","article-title":"Dose-Exposure Proportionality of a Novel Recombinant Follicle-Stimulating Hormone (rFSH), FE 999049, Derived from a Human Cell Line, with Comparison between Caucasian and Japanese Women after Subcutaneous Administration","volume":"35","author":"Olsson","year":"2015","journal-title":"Clin. Drug Investig."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1093\/humrep\/dez184","article-title":"Individualized ovarian stimulation in IVF\/ICSI treatment: It is time to stop using high FSH doses in predicted low responders","volume":"35","author":"Leijdekkers","year":"2020","journal-title":"Hum. Reprod."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.fertnstert.2019.12.025","article-title":"Time to pregnancy: As important for patients as underestimated by doctors","volume":"113","author":"Roque","year":"2020","journal-title":"Fertil. Steril."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"m2519","DOI":"10.1136\/bmj.m2519","article-title":"Freeze-all versus fresh blastocyst transfer strategy during in vitro fertilisation in women with regular menstrual cycles: Multicentre randomised controlled trial","volume":"370","author":"Stormlund","year":"2020","journal-title":"BMJ"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1093\/humrep\/deq125","article-title":"Circulating progesterone levels and ongoing pregnancy rates in controlled ovarian stimulation cycles for in vitro fertilization: Analysis of over 4000 cycles","volume":"25","author":"Bosch","year":"2010","journal-title":"Hum. Reprod."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.fertnstert.2014.12.114","article-title":"Comparison of antim\u00fcllerian hormone levels and antral follicle count as predictor of ovarian response to controlled ovarian stimulation in good-prognosis patients at individual fertility clinics in two multicenter trials","volume":"103","author":"Nelson","year":"2015","journal-title":"Fertil. Steril."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1093\/humupd\/dmu062","article-title":"Technical and performance characteristics of anti-M\u00fcllerian hormone and antral follicle count as biomarkers of ovarian response","volume":"21","author":"Iliodromiti","year":"2015","journal-title":"Hum. Reprod. Update"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/j.fertnstert.2012.12.048","article-title":"Antim\u00fcllerian hormone in gonadotropin releasing-hormone antagonist cycles: Prediction of ovarian response and cumulative treatment outcome in good-prognosis patients","volume":"99","author":"Arce","year":"2013","journal-title":"Fertil. Steril."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1093\/humupd\/dmu020","article-title":"Anti-M\u00fcllerian hormone: Ovarian reserve testing and its potential clinical implications","volume":"20","author":"Broer","year":"2014","journal-title":"Hum. Reprod. Update"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.rbmo.2016.07.003","article-title":"Anti-M\u00fcllerian hormone for prediction of ovarian response in Chinese infertile women undergoing IVF\/ICSI cycles: A prospective, multi-centre, observational study","volume":"33","author":"Li","year":"2016","journal-title":"Reprod. Biomed. Online"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1007\/s00404-020-05491-9","article-title":"Analysis of the women with the AMH concentrations below the limit of reference range but with the ideal number of retrieved oocytes","volume":"301","author":"Wu","year":"2020","journal-title":"Arch. Gynecol. Obstet."},{"key":"ref_73","unstructured":"(2022, December 22). Available online: https:\/\/www.deutsches-ivf-register.de\/perch\/resources\/dir-jahrbuch-2018-deutsch-4.pdf."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1111\/cts.13037","article-title":"First-in-human trial assessing the pharmacokinetic-pharmacodynamic profile of a novel recombinant human chorionic gonadotropin in healthy women and men of reproductive age","volume":"14","author":"Hesse","year":"2021","journal-title":"Clin. Transl. Sci."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1093\/humrep\/des256","article-title":"A randomized controlled dose\u2013response pilot study of addition of hCG to recombinant FSH during controlled ovarian stimulation for in vitro fertilization","volume":"27","author":"Thuesen","year":"2012","journal-title":"Hum. Reprod."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1095\/biolreprod51.1.72","article-title":"Folliculogenesis in Hypophysectomized Rats after Treatment with Recombinant Human Follicle-Stimulating Hormone","volume":"51","author":"Mannaerts","year":"1994","journal-title":"Biol. Reprod."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1023\/A:1020569508927","article-title":"Requirements for human chorionic gonadotropin and recombinant human luteinizing hormone for follicular development and maturation","volume":"16","author":"Andersen","year":"1999","journal-title":"J. Assist. Reprod. Genet."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/978-1-4684-3474-3_79","article-title":"hCG-induced loss of LH-hCG receptor and desensitization of adenylate cyclase","volume":"112","author":"Lee","year":"1979","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/S0015-0282(98)00332-X","article-title":"Timed analysis of the nuclear maturation of oocytes in early preantral mouse follicle culture supplemented with recombinant gonadotropin","volume":"70","author":"Cortvrindt","year":"1998","journal-title":"Fertil. Steril."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1095\/biolreprod.103.024471","article-title":"Regulation of Luteinizing Hormone\/Human Chorionic Gonadotropin Receptor Expression: A Perspective1","volume":"70","author":"Menon","year":"2004","journal-title":"Biol. Reprod."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.mce.2012.01.021","article-title":"Structure, function and regulation of gonadotropin receptors\u2014A perspective","volume":"356","author":"Menon","year":"2012","journal-title":"Mol. Cell. Endocrinol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1093\/humrep\/deg066","article-title":"Clinical evidence for an LH \u2018ceiling\u2019 effect induced by administration of recombinant human LH during the late follicular phase of stimulated cycles in World Health Organization type I and type II anovulation","volume":"18","author":"Loumaye","year":"2003","journal-title":"Hum. Reprod."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1093\/humrep\/deh682","article-title":"Does the addition of recombinant LH in WHO group II anovulatory women over-responding to FSH treatment reduce the number of developing follicles? A dose-finding study","volume":"20","author":"Hugues","year":"2005","journal-title":"Hum. Reprod."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1210\/jcem.86.1.7108","article-title":"Luteinzing Hormone Activity in Menotropins Optimizes Folliculogenesis and Treatment in Controlled Ovarian Stimulation","volume":"86","author":"Filicori","year":"2001","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1210\/jcem.87.3.8322","article-title":"Stimulation and Growth of Antral Ovarian Follicles by Selective LH Activity Administration in Women","volume":"87","author":"Filicori","year":"2002","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.fertnstert.2005.02.036","article-title":"Efficacy of low-dose human chorionic gonadotropin alone to complete controlled ovarian stimulation","volume":"84","author":"Filicori","year":"2005","journal-title":"Fertil. Steril."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"E1524","DOI":"10.1210\/jc.2012-1427","article-title":"LH-Receptor Gene Expression in Human Granulosa and Cumulus Cells from Antral and Preovulatory Follicles","volume":"97","author":"Jeppesen","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0950-3552(97)80036-3","article-title":"Role of androgens in follicle maturation and atresia","volume":"11","author":"Hillier","year":"1997","journal-title":"Baillieres. Clin. Obstet. Gynaecol."},{"key":"ref_89","first-page":"200","article-title":"Initial and Cyclic Recruitment of Ovarian Follicles","volume":"21","author":"McGee","year":"2000","journal-title":"Endocr. Rev."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"452","DOI":"10.3389\/fendo.2018.00452","article-title":"Androgen Action in the Ovary","volume":"9","author":"Franks","year":"2018","journal-title":"Front. Endocrinol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1093\/humrep\/15.7.1490","article-title":"Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: Results of a controlled, randomized, multicentre trial","volume":"15","author":"Group","year":"2000","journal-title":"Hum. Reprod."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Al-Inany, H.G., Youssef, M.A., Aboulghar, M., Broekmans, F., Sterrenburg, M., Smit, J., and Abou-Setta, A.M. (2011). Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database Syst. Rev., CD001750.","DOI":"10.1002\/14651858.CD001750.pub3"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.fertnstert.2018.02.132","article-title":"Premature progesterone elevation in controlled ovarian stimulation: To make a long story short","volume":"109","author":"Poulain","year":"2018","journal-title":"Fertil. Steril."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1016\/j.fertnstert.2013.08.045","article-title":"Progesterone elevation does not compromise pregnancy rates in high responders: A pooled analysis of in vitro fertilization patients treated with recombinant follicle-stimulating hormone\/gonadotropin-releasing hormone antagonist in six trials","volume":"100","author":"Griesinger","year":"2013","journal-title":"Fertil. Steril."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1055\/s-0032-1328878","article-title":"Obesity and PCOS: Implications for diagnosis and treatment","volume":"30","author":"Legro","year":"2012","journal-title":"Semin. Reprod. Med."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"579","DOI":"10.3389\/fendo.2019.00579","article-title":"FSH Requirements for Follicle Growth During Controlled Ovarian Stimulation","volume":"10","author":"Abbara","year":"2019","journal-title":"Front. Endocrinol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.rbmo.2011.04.002","article-title":"Corifollitropin alfa doses based on body weight: Clinical overview of drug exposure and ovarian response","volume":"23","author":"Ledger","year":"2011","journal-title":"Reprod. Biomed. Online"},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"(2004). Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil. Steril., 81, 19\u201325.","DOI":"10.1016\/j.fertnstert.2003.10.004"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ejogrb.2013.05.019","article-title":"Serum anti-mullerian hormone levels in the main phenotypes of polycystic ovary syndrome","volume":"170","author":"Sahmay","year":"2013","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.fertnstert.2018.05.004","article-title":"Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome","volume":"110","author":"Teede","year":"2018","journal-title":"Fertil. Steril."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1093\/humrep\/der297","article-title":"Diagnosis of polycystic ovary syndrome (PCOS): Revisiting the threshold values of follicle count on ultrasound and of the serum AMH level for the definition of polycystic ovaries","volume":"26","author":"Dewailly","year":"2011","journal-title":"Hum. Reprod."},{"key":"ref_102","first-page":"214","article-title":"Comparison of the automated Roche Elecsys Cobas Anti Mullerian Hormone (AMH) assay with the Beckman AMH Gen II ELISA","volume":"41","author":"Inia","year":"2016","journal-title":"Ned. Tijdschr. Klin. Chem. Labgeneesk."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"e391","DOI":"10.1016\/j.fertnstert.2019.07.1116","article-title":"Establishing an anti-m\u00fcllerian hormone (AMH) cut-off to determine polycystic ovarian morphology (PCOM) supporting diagnosis of polycystic ovarian syndrome (PCOS): The aphrodite study","volume":"112","author":"Hund","year":"2019","journal-title":"Fertil. Steril."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1093\/humrep\/det469","article-title":"The prevalence of polycystic ovary syndrome in a normal population according to the Rotterdam criteria versus revised criteria including anti-M\u00fcllerian hormone","volume":"29","author":"Lauritsen","year":"2014","journal-title":"Hum. Reprod."}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/13\/2\/177\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T17:58:37Z","timestamp":1760119117000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/13\/2\/177"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,4]]},"references-count":104,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["diagnostics13020177"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics13020177","relation":{},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,4]]}}}